Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034


The 7 major allergic rhinitis markets reached a value of US$ 3,610.7 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 5,078.0 Million by 2034, exhibiting a growth rate (CAGR) of 3.15% during 2024-2034.

The allergic rhinitis market has been comprehensively analyzed in IMARC's new report titled "Allergic Rhinitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Allergic rhinitis, or hay fever, is a type of nasal inflammation caused by the immune system overreacting to allergens in the air. This reaction causes the mucous membrane of the nose to release a variety of chemicals, causing the nose to swell and produce an excessive amount of mucus. Some of the common symptoms are sneezing, nasal congestion, clear rhinorrhea, nasal pruritus, postnasal drip, etc. Individuals suffering from allergic rhinitis may also experience conjunctival swelling and erythema, lower eyelid venous stasis, eyelid swelling, middle ear effusion, swollen nasal turbinates, etc. The diagnosis of allergic rhinitis typically involves a combination of patient history, physical examination, and allergy testing. Medical history and physical examination can provide information on the duration and frequency of symptoms, as well as any associated conditions, such as asthma. Allergy testing may involve skin prick tests or blood tests to identify specific allergens triggering the allergic reaction. Various additional investigations, including nasal endoscopy, may be performed to rule out other potential causes of symptoms.

The increasing prevalence of allergic reactions to various allergens, such as pollen, pet dander, dust mites, mold, etc., is primarily driving the allergic rhinitis market. Moreover, the escalating utilization of topical nasal corticosteroids, since they aid in reducing inflammation in the nasal passages and alleviate symptoms, including congestion, sneezing, runny nose, etc., is also bolstering the market growth. Besides this, the widespread adoption of rhinomanometry, which measures the resistance of airflow through the nasal passages to identify any blockages or narrowing that may be causing the ailment, is acting as another significant growth-inducing factor. Additionally, the ongoing development of advanced drug delivery systems, such as nasal sprays and inhalers, is improving the efficacy and convenience of treatment for allergic rhinitis patients, thereby propelling the market growth. Furthermore, the rising application of the basophil activation test, which reduces the need for in-vivo procedures and specifically detects all the characteristics of IgE and allergens in the diagnosis of allergic disease, is positively influencing the market. Apart from this, the emerging popularity of sublingual allergen immunotherapy owing to its several associated benefits, including ease of self-administration and reduced risk for systemic reactions, is expected to drive the allergic rhinitis market during the forecast period.

IMARC Group’s new report provides an exhaustive analysis of the allergic rhinitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for allergic rhinitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the allergic rhinitis market in any manner.

Time Period of the Study

Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034

Countries Covered

United States
Germany
France
United Kingdom
Italy
Spain
Japan

Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario
Historical, current, and future performance of the allergic rhinitis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the allergic rhinitis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current allergic rhinitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:
Market Insights

How has the allergic rhinitis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the allergic rhinitis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the allergic rhinitis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?

Epidemiology Insights

What is the number of prevalent cases (2018-2034) of allergic rhinitis across the seven major markets?
What is the number of prevalent cases (2018-2034) of allergic rhinitis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of allergic rhinitis by gender across the seven major markets?
What is the number of prevalent cases (2018-2034) of allergic rhinitis by type across the seven major markets?
How many patients are diagnosed (2018-2034) with allergic rhinitis across the seven major markets?
What is the size of the allergic rhinitis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of allergic rhinitis?
What will be the growth rate of patients across the seven major markets?

Allergic Rhinitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for allergic rhinitis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the allergic rhinitis market?
What are the key regulatory events related to the allergic rhinitis market?
What is the structure of clinical trial landscape by status related to the allergic rhinitis market?
What is the structure of clinical trial landscape by phase related to the allergic rhinitis market?
What is the structure of clinical trial landscape by route of administration related to the allergic rhinitis market?


1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Allergic Rhinitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Allergic Rhinitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Allergic Rhinitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Epidemiology by Type (2018-2034)
7.2.6 Diagnosed Cases (2018-2034)
7.2.7 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Epidemiology by Type (2018-2034)
7.3.6 Diagnosed Cases (2018-2034)
7.3.7 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Epidemiology by Type (2018-2034)
7.4.6 Diagnosed Cases (2018-2034)
7.4.7 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Epidemiology by Type (2018-2034)
7.5.6 Diagnosed Cases (2018-2034)
7.5.7 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Epidemiology by Type (2018-2034)
7.6.6 Diagnosed Cases (2018-2034)
7.6.7 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Epidemiology by Type (2018-2034)
7.7.6 Diagnosed Cases (2018-2034)
7.7.7 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Epidemiology by Type (2018-2034)
7.8.6 Diagnosed Cases (2018-2034)
7.8.7 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Epidemiology by Type (2018-2034)
7.9.6 Diagnosed Cases (2018-2034)
7.9.7 Patient Pool/Treated Cases (2018-2034)
8 Allergic Rhinitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Allergic Rhinitis - Unmet Needs
10 Allergic Rhinitis - Key Endpoints of Treatment
11 Allergic Rhinitis - Marketed Products
11.1 List of Allergic Rhinitis Marketed Drugs Across the Top 7 Markets
11.1.1 Odactra (House dust mite allergy immunotherapy) - ALK-Abello
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Grastek (Grass pollen allergy vaccine tablet) - ALK-Abello
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Clarinex (Desloratadine) - Merck & Co
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Astelin (Azelastine) - Meda
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5 Xyzal (Levocetirizine) - Sanofi-Aventis/UCB
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 Allergic Rhinitis - Pipeline Drugs
12.1 List of Allergic Rhinitis Pipeline Drugs Across the Top 7 Markets
12.1.1 IRL 201104 - Revolo Biotherapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 REGN5713 5714 5715 - Regeneron Pharmaceuticals
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 Grass MATA MPL - Allergy Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 MM09 - Inmunotek
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Allergic Rhinitis - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Allergic Rhinitis – Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Allergic Rhinitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Allergic Rhinitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Allergic Rhinitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Allergic Rhinitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Allergic Rhinitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Allergic Rhinitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Allergic Rhinitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Allergic Rhinitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Allergic Rhinitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Allergic Rhinitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Allergic Rhinitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Allergic Rhinitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Allergic Rhinitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Allergic Rhinitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Allergic Rhinitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Allergic Rhinitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Allergic Rhinitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Allergic Rhinitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Allergic Rhinitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Allergic Rhinitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Allergic Rhinitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Allergic Rhinitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Allergic Rhinitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Allergic Rhinitis - Access and Reimbursement Overview
16 Allergic Rhinitis - Recent Events and Inputs From Key Opinion Leaders
17 Allergic Rhinitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Allergic Rhinitis Market – Strategic Recommendations
19 Appendix

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings